Tuesday, July 17, 2018
 
 
Company News: Page (1) of 1 - 07/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Inspirotec Inc.: Study Results Show Allergy Patients Can Run Air Sampling Device and Determine Normal Range of Allergens in Air of Homes

(July 12, 2018)

Results of first of its kind field study In Press in Annals of Allergy, Asthma and Immunology

CHICAGO, July 12, 2018 (GLOBE NEWSWIRE) -- Inspirotec Inc., a Chicago-based startup company with proprietary technology for measuring airborne allergens, today announced that the results of its field study, which shows that patients can run the air sampling device in their own homes and obtain statistically significant data, will be published in the Annals of Allergy, Asthma and Immunology (www.annallergy.org/article/S1081-1206(18)30390-9/fulltext). The results show normal ranges for common household airborne allergens and conditions that can affect those values.

Utilizing the innovative home-based study, combined with Inspirotec’s cutting edge laboratory analysis, concentrations of dust mite, cat, dog, mouse, rat, mold, and pollen allergens were found for each individual home in 103 homes.

Allergists from five medical practices recruited patients to run the tests. They provided patients with instructions and packages to take home, plug in their bedrooms to test the air there for a few days, and patients returned them to their doctors.



“Our study shows that it is now possible for patients to know the airborne allergens in their own homes, and take targeted remedial measures that will enable them to eliminate allergens that are triggering their symptoms, and of which they may have been totally unaware.  This kind of analysis and service has not been available to them previously,” says Julian Gordon PhD, leading scientist in the study and co-founder of Inspirotec. “Previous studies of this kind have required the intrusion of skilled technicians to run bulky, noisy, equipment. Further, analysis was done on settled dust, not on the air, as it was believed that the amounts in the air were often too low to measure, despite the fact that it is the inhaled material in the air that causes symptoms.” Lead physician and clinical consultant to Inspirotec, Paul Detjen MD says, “This fills a hole in our ability to do complete patient management. Previously, this kind of information was available only anecdotally from the patient, but we can now get objective numbers.”

Dr. Gordon continues: “Because this kind of data was previously unavailable, there are no standards for concentrations of allergens in the air that are accepted as being dangerous. The best we can do is to use our data to compare results with average levels in similar homes. This is just like when the electricity provider tells you how your consumption compares with similar homes. This data provides such a framework.”

The only comparable work was a large nation-wide study by a group at the National Institutes of Health (NIH), where analysis was made of vacuumed dust in homes. They defined “Exposure Intensity” by the number of different allergens detected in a home. Inspirotec compared their results in Chicago with the nation-wide results from the NIH.

Some allergen levels were found to be significantly lower at lower humidity and where HEPA-filter air cleaning was used. This attests to the statistical significance of the data.

About Inspirotec Inc.
Inspirotec Inc is the only company providing airborne allergen detection either through physicians or direct to consumer. Direct to consumer is marketed under the brand name Exhale and can be purchased through www.exhalenow.com.

Inspirotec has an extensive portfolio of patents* as well as prior publications in the peer-reviewed literature1-3.

*US patents 8,038,944, 9,216,421, 9,360,402, 9,481,904, 9,618,431 as well as patents and application world-wide.
1Gordon J, Gandhi P, Shekhawat G, Frazier A, Hampton-Marcell J, Gilbert JA. A simple novel device for air sampling by electrokinetic capture. Microbiome. 2015;3.
2Gordon J, Detjen P, Kelso D, Gandhi P. A new patient-operated sampling device for measurement of aeroallergens. Ann Allergy Asthma Immunol. 2016;116(5):475-6.
3Gordon J, Reboulet R, Gandhi P, Matsui E. Validation of a novel sampling technology for airborne allergens in low-income urban homes. Ann Allergy Asthma Immunol. 2018;120(1):96-97.

Contact
Rachel Reboulet
(513) 907-1007
[email protected]


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Personal Care Home Consultant Lynn Marting Helps Families Find the Right Facility for Aging Loved Ones
  • Mount Sinai Health System and Arena Address AI-Driven Hiring for Healthcare at Leading Industry Conference
  • Connected Health Devices: Global Market Forecast to 2023 - CAGR to Grow at 21.1%, Driven by the Increasing Adoption of IT in Healthcare
  • Global Special Purpose Needles Industry
  • Gregory J. Paul, MA Honored as a Top Executive by Strathmore's Who's Who Worldwide Publication

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Global Rice Bran Oil Market Professional Survey Report, 2018 by Radiant Insights
  • RiMO Therapeutics Announces Enrollment of the First Patient in Phase 1 Study of RiMO-301 With Radiation in Advanced Tumors
  • Patient Advocate Foundation Receives Grant to Advance Cost of Care Conversations between Patients and Health Care Providers
  • CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines